{
    "clinical_study": {
        "@rank": "141243", 
        "arm_group": [
            {
                "arm_group_label": "A -Tace alone", 
                "arm_group_type": "Other", 
                "description": "A - TACE alone (control group, current practice and treatment)"
            }, 
            {
                "arm_group_label": "B - Tace combined with SBRT", 
                "arm_group_type": "Experimental", 
                "description": "B- TACE combined with SBRT (experimental group)."
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is designed to be the initial prospective pilot investigation of the\n      effectiveness of combined SBRT and TACE as bridging therapy for HCC patients awaiting liver\n      transplanation. No prospective clinical trials regarding the combination of TACE and SBRT in\n      pre-transplant population have been performed. We propose the trial be conducted as a pilot\n      clinical trial with the goal of enrolling 40 patients into each arm"
        }, 
        "brief_title": "TACE With or Without SBRT as Bridging Therapy for Pre-transplant HCC Patients", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatocellular Carcinoma Within Milan Criteria for Liver Tranplantation", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Hepatocellular"
            ]
        }, 
        "detailed_description": {
            "textblock": "The purpose of this study is to determine whether the combination of stereotatic body\n      radiotherapy (SBRT) tand transarterial chemoembolization (TACE) is an effective \"bridging\n      therapy\" for patients hepatocellular carcinoma (HCC) of the liver awaiting transplantation."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Capable of giving informed consent; diagnosed with HCC and listed for OTL at the\n        participating institution in accordance with OPTN guidelines(single tumor less than 5cm;up\n        to 3 tumors all less than 3cm; no gross vascular invasion or regional nodal or distant\n        metastasis); age equal to or greater than 18 years old; albumin greater than 2.4g/dL;\n        total bilirubin less than 2 mg/dL; INR less than or equal to + 1.5; creatinine less than\n        2.0mg/dL; Child's class A or B7; ECOG 0 or 1 All subjects who meet the above criteria and\n        are referred for bridging TACE prior to OTL at Penn will be approached for participation\n        in this study. There are no plans to limit participation based on age or gender.\n\n        Exclusion Criteria:\n\n          -  Prior radiotherapy to the upper abdomen; Prior TACE, RFA, or liver transplant; Active\n             GI bleed within 2 weeks of study enrollment; active GI ulcer disease within 4 weeks\n             of study enrollment; ascites refractory to medical therapy; contraindication to\n             receiving radiotherapy or TACE; complete obstruction of portal venous flow to the\n             segment of liver that includes the target lesion; contraindication to both contrast\n             enhanced MRI and contrast enhanced CT (i.e., unable to undergo follow-up imaging or\n             SBRT treatment planning); women who are pregnant; participation in another concurrent\n             treatment protocol. There will be no exclusion based on other factors."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01918683", 
            "org_study_id": "UPCC 16213"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "A -Tace alone", 
                    "B - Tace combined with SBRT"
                ], 
                "intervention_name": "TACE transarterial chemoembolization", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": "B - Tace combined with SBRT", 
                "intervention_name": "stereotatic body radiotherapy (SBRT)", 
                "intervention_type": "Radiation"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "August 7, 2013", 
        "location": {
            "contact": {
                "email": "PennCancerTrials@emergingmed.com", 
                "last_name": "Edgar Ben-Josef, MD", 
                "phone": "877-204-9213"
            }, 
            "facility": {
                "address": {
                    "city": "Philadelphia", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "19104"
                }, 
                "name": "Abramson Cancer Center of the University of Pennsylvania"
            }, 
            "investigator": {
                "last_name": "Edgar Ben-Josef, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Pilot Trial of Transarterial Chemoembolization With or Without Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma Patients Awaiting Liver Transplantation", 
        "overall_contact": {
            "email": "PennCancerTrials@emergingmed.com", 
            "last_name": "Edgar Ben-Josef, MD", 
            "phone": "877-204-9213"
        }, 
        "overall_official": {
            "affiliation": "Abramson Cancer Center of the University of Pennsylvania", 
            "last_name": "Edgar Ben-Josef, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 0", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression Free Survival", 
            "safety_issue": "Yes", 
            "time_frame": "10 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01918683"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Abramson Cancer Center of the University of Pennsylvania", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Abramson Cancer Center of the University of Pennsylvania", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}